Join
Live feed
·
PRReleasevia Quantisnow
FibroGen Inc logo
Kyntra Bio Inc. logo

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

ByQuantisnow·Wall Street's wire, on your screen.
FGEN· FibroGen IncKYNB· Kyntra Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FGEN (FibroGen Inc), KYNB (Kyntra Bio Inc.) and more on Quantisnow.

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 | Quantisnow